Characterization of series arcs in LVdc microgrids
This paper provides an empirical study on series arc behavior in low voltage dc microgrids. The response of an R-L-C dc microgrid abstraction towards series arcs is studied experimentally for varying grid inductance, dc voltages, load capacitances and load currents. In order to account for the stochastic nature of arcs, experiments are repeated multiple times under similar conditions to gain statistical significance. Thereby, insight on percentage occurrence and burn time of initiated series arcs is provided. Load side voltage response is studied to gain insight on the expected peak drop and fall time. This empirical evidence was judged to be a necessary requirement in developing a novel series arc extinguishing method from load side power electronic devices.
Comparison of AC and DC Nanogrid for Office Buildings with EV Charging, PV and Battery Storage
Future office buildings are expected to be integrated with energy intensive, inherently DC components such as photovoltaic panels (PV), electric vehicles (EV), LED lighting, and battery storage. This paper conceptualizes the interconnection of these components through a 750 V DC nanogrid as against a conventional three-phase 400 V AC system. The factors influencing the performance of a DC-based nanogrid are identified and a comparative analysis with respect to a conventional AC nanogrid is presented in terms of efficiency, stability, and protection. It is proved how the minimization of grid energy exchange through power management is a vital system design choice. Secondly, the trade-off between stability, protection, and cost for sizing of the DC buffer capacitors is explored. The transient system response to different fault conditions for both AC and DC nanogrid is investigated. Finally the differences between the two systems in terms of various safety aspects are highlighted.
Antitumor activities of (2"R)-4'-O-tetrahydropyranyl-adriamycin (THP) and its combination with other antitumor agents on murine tumors.
(2''R)-4'-O-Tetrahydropyranyladriamycin (THP) is a new derivative of doxorubicin (adriamycin, ADM). The concentrations of THP and ADM required to inhibit by 50% the growth of a cultured L1210 cells was 0.003 microgram/ml and 0.016 microgram/ml, respectively. Various therapeutic designs of combinations of THP with other antitumor agents were investigated in vivo using the L1210 murine leukemia. The combination of THP with cytosine arabinoside (Ara-C), cyclocytidine hydrochloride (Cyclo-C), 6-mercaptopurine (6-MP) and cyclophosphamide (EX) showed a great effectiveness following daily intraperitoneal treatment from days 1 to 10. High therapeutic effects were also obtained with the combinations of THP with Ara-C, Cyclo-C, vincristine (VCR) and EX following intravenous combination therapy one day following implantation of L1210 leukemia. Schedule dependency and its therapeutic efficacy of THP were examined. THP showed almost the same antitumor activity on the solid-type sarcoma-180 or solid-type Ehrlich carcinoma as ADM by intraperitoneal or intravenous treatment. THP showed some superior activity to ADM in the advanced stage of L1210 leukemia. High antitumor activity of THP on murine leukemia L1210 has been reported by Tsuruo et al. (Cancer Res. 42: 1462-1467, 1982) and was also confirmed. THP gave many mice cures, especially in the intravenous treatment.